Taiwan Biomaterial Co., Ltd.
Taiwan Biomaterial Co., Ltd. engages in the development and sale of implantable medical devices in Taiwan. It offers Foamagen, a foamagen dura substitute; stroke thrombus negative pressure removal catheter system comprising suction and removal of cerebrovascular embolism blood clot for the pump system, and nickel-titanium guidewire for guiding cerebral vascular surgery; tissue repair and regenera… Read more
Taiwan Biomaterial Co., Ltd. (6649) - Net Assets
Latest net assets as of : NT$- TWD
Based on the latest financial reports, Taiwan Biomaterial Co., Ltd. (6649) has net assets worth NT$- TWD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$-) and total liabilities (NT$-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Taiwan Biomaterial Co., Ltd. - Net Assets Trend (None–None)
This chart illustrates how Taiwan Biomaterial Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Taiwan Biomaterial Co., Ltd. (None–None)
The table below shows the annual net assets of Taiwan Biomaterial Co., Ltd. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Taiwan Biomaterial Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Taiwan Biomaterial Co., Ltd. Competitors by Market Cap
The table below lists competitors of Taiwan Biomaterial Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ZHONGSHENG GRP
BE:5Z0
|
$11.84K |
|
Myungmoon Pharmaceutical Co. Ltd.
KQ:017180
|
$11.85K |
|
DIAMOND TRUST BANK KENYA LTD
XNAI:DTB
|
$11.86K |
|
EPRCOMUNICAZIONE S.P.A.
F:J3P
|
$11.86K |
|
AZPL11
SA:AZPL11
|
$11.82K |
|
NUFARM (NUF.SG)
STU:NUF
|
$11.80K |
|
DEXP4F
SA:DEXP4F
|
$11.79K |
|
MULBERRY GROUP
BE:MUY
|
$11.77K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Taiwan Biomaterial Co., Ltd.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Taiwan Biomaterial Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Taiwan Biomaterial Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Taiwan Biomaterial Co., Ltd.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,274,214,400
- Average return on equity (ROE) among peers: 6.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Taiwan Biomaterial Co., Ltd. (6649) | NT$- | N/A | N/A | $11.84K |
| Health & Life Co., Ltd. (1781) | $372.58 Million | -4.71% | 1.15x | $12.97 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.65 Million |
| Wellell Inc (4106) | $1.31 Billion | 13.81% | 0.24x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.33 Billion | 1.93% | 1.30x | $38.32 Million |
| United Orthopedic (4129) | $1.77 Billion | 7.55% | 0.46x | $300.33 Million |
| Dynamic Medical Technologies (4138) | $1.76 Billion | 11.67% | 0.71x | $39.41 Million |
| Ok Biotech Co Ltd (4155) | $1.30 Billion | 9.66% | 0.71x | $44.61 Million |
| Bioptik Technology (4161) | $717.83 Million | 6.76% | 1.11x | $30.42 Million |
| EPS Bio Technology Corp. (4183) | $309.15 Million | 10.25% | 0.77x | $4.27 Million |